Yazar "Dalmaz, Mahmut" seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Effect of Anti-Hcv Positivity on Response to Hepatitis B Virus Vaccine in Haemodialysis Patients(1998) Koşar, Ali; Dalmaz, Mahmut; Sağmanlıgil, Şerife; Yeksan, Mehdi; Türk, SüleymanThere are different factors that affect the response of recombinant hepatitis B vaccine in hemodialysis patients. A total of 36 patients on a hemodialysis program (HD) were included in this study; 17 of patients were anti-HCV-positive and 19 were anti-HCV-negative. All serological markers of anti-HBs, HBs, anti-HBc IgM and anti-HBc total were negative in all patients. A 20 g dose of vaccine (Genhevac B Pasteur Merieux, France) was given intramuscularly at 0, 1 and 6 months. Anti-HBs levels were measured at 1, 2, 7 and 16 months and an anti-HBs titer>10 IU/mL was accepted as a protective level against hepatitis B virus infection. At 1, 2 and 7 months there was no statistically significant difference between these groups according to anti- HBs levels. However, anti-HBs levels were lower in anti-HCV-positive group at the 16th month (p<0.05). Anti-HCV positivity in HD patients has a negative effect on the antibody response to hepatitis B virus vaccine. This can be a result of the hepatitis or of the effect on the immune system which is caused by HCV. This negative effect could not be explained in this study and we believe more studies should be carried out in selected patients and larger series.Öğe The role of endothelin and prostacyclin on recombinant erythropoietin- ? induced hypertension in hemodialysis patients(2013) Türkmen, Kültigin; Erdur, Fatih Mehmet; Dalmaz, Mahmut; Yeksan, Mehdi; Akkuş, İdris; Türk, SüleymanOBJECTIVE: Recombinant human erythropoietin (r-HuEPO) was found to be associated with increased blood pressure in hemodialysis (HD) patients. Plasma endothelin-1(ET-1) was reported to be increased during treatment with r-huEPO in HD patients. Prostacyclin (PGI2) was found to be associated with the reduction in vascular resistance. We aimed to determine the role of ET-1 and PGI2 on r-huEPO-induced hypertension in HD patients. MATERIAL and Methods: 43 HD patients (19 females, 24 males) were randomly assigned to groups. Group 1 (n=15) consisted of patients receiving r-HuEPO-? subcutaneously after each dialysis session for 6 to 42 months. Group 2 (n=15, control group) consisted of patients who did not receive any r-huEPO and group 3 (n=13) consisted of patients who received r-huEPO-? subcutaneously after each dialysis session for 12 weeks. Plasma ET-1,2 and 6-keto-PGF1-? were measured. Results : There were no differences in terms of ET-1,2 and 6-keto-PGF1-?, systolic and diastolic BP and hematocrit levels in group 1 and group 2 patients. However, in group 3 patients, hematocrit, plasma ET1,2 and 6-keto PGF1-? levels were significantly elevated after 12 weeks of rHuEPO treatment. Conclusion: We showed that ET-1.2 and 6-keto-PGF1-? levels were found to be significantly increased with 12 weeks of rHu-EPO therapy in HD patients.Öğe The role of endothelin and prostacyclin on recombinant erythropoietin-? ınduced hypertension in hemodialysis patients(2013) Türkmen, Kültigin; Erdur, Fatih Mehmet; Dalmaz, Mahmut; Yeksan, Mehdi; Türk, Süleyman; Akkuş, İdrisAMAÇ: Hemodiyaliz (HD) hastalarında renal aneminin tedavisinde kullanılan rekombinan insan eritropoetin (rHuEPO) tedavisi artmış kan basıncı ile ilişkili bulunmuştur. Plazma endotelin 1 (ET1) konsantrasyonlarının hemodiyaliz hastalarında rHuEPO tedavisi esnasında yükseldiği tespit edilmiştir. Prostasiklin (PGI2) önemli bir vasodilatör madde olup vasküler dirençte azalma ile ilişkili bulunmuştur. Hemodiyaliz hastalarında rHuEPO ile ilişkili hipertansiyonda ET-1 ve PGI2 etkisini araştırmayı hedefledik. Gereç ve yöntemLER: 43 HD hastası (19 kadın, 24 erkek) rastgele olarak gruplara ayrıldı. Grup 1deki hastalar (n15), 6-42 ay boyunda her diyaliz seansı sonunda subkutan rHuEPO-? kullanan hastalar, grup 2deki hastalar (n15, kontrol grubu) hiç r-huEPO almayan hastalar, ve grup 3teki hastalar (n13) 12 hafta boyunca her diyaliz sonrasında subkutan rHuEPO-? kullanan hastalardı. Plazmada ET-1,2 ve 6-keto-PGF1-? ölçüldü. Bulgular: Grup 1 ve 2deki hastalarda tedavi öncesinde ve sonrasında hematokrit, ET-1,2 ve 6-keto-PGF1-? düzeyleri ve sistolik ve diyastolik kan basınçları açısından bir fark saptanmadı. Bununla birlikte, grup 3 hastalarda 12 haftalık rHuEPO tedavisi sonrasında hematokrit, ET-1,2 ve 6-keto-PGF1-? düzeyleri anlamlı düzeyde artmış bulundu. Sonuç: Çalışmamızda, HD hastalarında 12 haftalık rHu-EPO tedavisi ile ET-1.2 ve 6-keto-PGF1- ?nın anlamlı olarak arttığını saptadık.Öğe Serum amyloid A protein levels in haemodialysis patients(Oxford University Press, 1996) Polat, H.; Yeksan, Mehdi; Dalmaz, Mahmut; Kaptanoğlu, B.; Koşar, A.; Akkuş, İdris[Abstract not Available]
